Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nebulized HCQ01 in COVID-19 Cancer Patients
NCT04731051Phase 2Withdrawn
- Sponsor
- King Hussein Cancer Center
- Start
- Oct 2022
- Primary completion
- Nov 2022
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ISPM19 in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by King Hussein Cancer Center. Primary endpoint: Proportion of participants who improve by at least one level lower on the 11-point World Health Organization Ordinal Scale for Clinical Improvement at Day 14. Planned start Oct 2022; status: withdrawn.
02
Drugs
ISPM19
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04731051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04731051.